维眸生物科技（浙江）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology 2025-08-13 00:00
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies. 2025-06-10 00:00
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis 2025-04-25 00:00
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery 2024-12-04 00:00
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma 2023-06-05 08:00
VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease 2022-03-23 08:00
1